报价延迟最少15分钟:2025/07/21 18:48 EDT
盘后时段
|
||||
|
21.81 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
21.81
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-3.65/-2.59
|
|
企业价值
1.91B
|
| 资产负债 |
|
每股账面净值
11.69
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
7.00M
|
|
每股收益
0.27
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/07/21 18:48 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs. |
